Business Development in Pharmaceuticals and Medical Devices

In-Licensing Services for Distributors

Currently available In-Licensing opportunities

Uracyst 2%
Uracyst is indicated in the treatment of interstitital cystitis (and used off label in a number of other cytitic conditions). Uracyst’s active ingredient is chondroitin sulphate and is marketed under a CE mark as a medical device. The licensor is Stellar Pharmaceuticals of Canada, who are the original developers of Uracyst.

Bosfor has a mandate from Stellar for finding exclusive distributors for Uracyst 2% outside the Americas. Uracyst 2% has recently been out- licenced to Galen for UK and Irish territories, to EIP in Turkey, to Eurocept for Benelux territories and to Vitaflo for Sweden, Norway, Denmark, Finland and Iceland, in which territories Uracyst 2% has just been launched. Agreement has just been reached with Sigmar for Italy. The remaining territories are available for discussion.